MDxHealth

MDxHealth, based in Irvine, California, and Herstal, Belgium, founded in 2003 and listed as MDXH, is a prostate diagnostics company that bought the Oncotype DX Genomic Prostate Score from Exact Sciences and sells the Select mdx and Confirm mdx tests. Its portfolio spans the pre-biopsy urine test Select mdx, the post-negative-biopsy methylation test Confirm mdx, the Genomic Prostate Score acquired in 2022 and Resolve mdx for urinary tract infections, and it moved its headquarters from Belgium to California in 2023. OnCo links it to prostate cancer, active surveillance and the Genomic Prostate Score record. Whether a suite of tests can reduce unnecessary biopsies and support active surveillance without missing aggressive disease is the question its products address. The Genomic Prostate Score has its own page.